Assessment of autoantibodies against 21-hydroxylase in the diagnosis of primary autoimmune adrenal insufficiency

Primary adrenal insufficiency is manifested by a deficiency of adrenal cortex hormones and can lead to a life-threatening condition. Early diagnosis is key to patient survival. Auto-antibodies to one of the adrenal steroidogenesis enzymes, 21-hydroxylase, are an immunological marker of autoimmune adrenal insufficiency. On the one hand, the study of antibodies to 21-hydroxylase is a method that helps establish the etiology of the disease – the autoimmune genesis of adrenal gland damage. On the other hand, the determination of autoantibodies to 21-hydroxylase is the only prognostic factor of the risk of adrenal insufficiency, which makes it possible to prevent the development of acute adrenal crisis. The article provides a brief literature review on autoantibodies to 21-hydroxylase and the pathogenesis of autoimmune adrenal insufficiency, and a series of clinical cases that illustrates the significant role of autoantibodies to 21-hydroxylase in diagnosis of adrenal insufficiency.

1. Федеральные клинические рекомендации (протоколы) по ведению детей с эндокринными заболеваниями. Под ред. Дедова И.И. и Петерковой В.А. М.: Практика; 2014. Federal’nye klinicheskie rekomendatsii (protokoly) po vedeniyu detei s endokrinnymi zabolevaniyami. Ed by Dedov I.I., Peterkova V.A. M.: Praktika; 2014. (In Russ.).

2. Dunlop D. Eighty-six cases of Addison’s disease. Br Med J. 1963; 2(5362):887-891. doi: https://doi.org/10.1136/bmj.2.5362.887

3. Betterle C, Scarpa R, Garelli S, et al. Addison’s disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013;169(6):773-784. doi: https://doi.org/10.1530/EJE-13-0528

4. Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009;94(12):4882-4890. doi: https://doi.org/10.1210/jc.2009-1368

5. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison’s disease underestimated? J Clin Endocrinol Metab. 1999;84(5):1762. doi: https://doi.org/10.1210/jcem.84.5.5677-7

6. Willis AC, Vince FP. The prevalence of Addison’s disease in Coventry, UK. Postgrad Med J. 1997;73(859):286-288. doi: https://doi.org/10.1136/pgmj.73.859.286

7. Betterle C, Morlin L. Autoimmune Addison’s disease. Endocr Dev. 2011;20:161-172. doi: https://doi.org/10.1159/000321239

8. Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546-3556. doi: https://doi.org/10.1210/jc.2017-00139

9. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: https://doi.org/10.1210/jc.2015-1710

10. Extract of Suprarenal Cortex in the Treatment of Addison’s Disease. Edinb Med J. 1932;39(4):268-270.

11. Anderson JR, Goudie RB, Gray K, Timbury GC. Auto-antibodies in Addison’s disease. Lancet. 1957;269(6979):1123-1124. doi: https://doi.org/10.1016/s0140-6736(57)91687-2

12. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet. 1992;339(8809): 1559-1562. doi: https://doi.org/10.1016/0140-6736(92)91829-w

13. Boscaro M, Betterle C, Volpato M, et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J Clin Endocrinol Metab. 1996;81(8):2801-2804. doi: https://doi.org/10.1210/jcem.81.8.8768833

14. Rottembourg D, Deal C, Lambert M, et al. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison’s disease. J Autoimmun. 2010;35(4):309-315. doi: https://doi.org/10.1016/j.jaut.2010.07.001

15. Wolff AS, Mitchell AL, Cordell HJ, et al. CTLA-4 as a genetic determinant in autoimmune Addison’s disease. Genes Immun. 2015;16(6):430-436. doi: https://doi.org/10.1038/gene.2015.27

16. Blomhoff A, Lie BA, Myhre AG, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison’s disease. J Clin Endocrinol Metab. 2004;89(7):3474-3476. doi: https://doi.org/10.1210/jc.2003-031854

17. Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R. The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals. Nat Immunol. 2014;15(9):875-883. doi: https://doi.org/10.1038/ni.2958

18. Skinningsrud B, Husebye ES, Gervin K, et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. Eur J Hum Genet. 2008;16(8):977-982. doi: https://doi.org/10.1038/ejhg.2008.33

19. Mitchell AL, Cordell HJ, Soemedi R, et al. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison’s disease and Graves’ disease susceptibility. J Clin Endocrinol Metab. 2009;94(12):5139-5145. doi: https://doi.org/10.1210/jc.2009-1404

20. de Filette J, Andreescu C, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(3):145-156. doi: https://doi.org/10.1055/a-0843-3366

21. Hellesen A, Bratland E, Husebye ES. Autoimmune Addison’s disease – an update on pathogenesis. Ann Endocrinol (Paris). 2018; 79(3):157-163. doi: https://doi.org/10.1016/j.ando.2018.03.008

22. Eriksson D, Bianchi M, Landegren N, et al. Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison’s disease in Sweden. Sci Rep. 2018;8(1):8395. doi: https://doi.org/10.1038/s41598-018-26842-2

23. Betterle C, Garelli S, Presotto F, Furmaniak J. From appearance of adrenal autoantibodies to clinical symptoms of Addison’s disease: natural history. Front Horm Res. 2016;46:133-145. doi: https://doi.org/10.1159/000443872